Soft Tissue Allograft Market Report 2025

The soft tissue allograft market size has grown strongly in recent years. It will grow from $4.51 billion in 2024 to $4.87 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period is linked to increasing demand for orthopedic reconstruction surgeries, rising prevalence of sports-related injuries, growing use of allografts in dental and periodontal treatments, expansion of wound and burn management procedures, and greater preference for minimally invasive surgical options.

The soft tissue allograft market size is expected to see strong growth in the next few years. It will grow to $6.5 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth projected for the forecast period is driven by a growing geriatric population with musculoskeletal disorders, rising adoption of biologic grafts in reconstructive surgery, expansion of healthcare infrastructure in emerging economies, growth in regenerative medicine applications, and increasing acceptance of allografts over synthetic alternatives. Primary trends during the forecast period include technological advancements in tissue processing methods, innovations in sterilization and preservation techniques, developments in decellularization and acellular grafts, increased investment in research and development for enhanced graft quality, and progress in imaging and surgical planning tools.

The growing preference for minimally invasive procedures is expected to drive expansion in the soft tissue allograft market moving forward. Minimally invasive procedures involve medical treatments performed through small incisions or openings, which reduce patient trauma and shorten recovery times. Demand for these procedures is rising because they offer quicker recovery, fewer complications, less pain, and smaller scars, making them attractive to patients seeking safer and faster treatment options. Soft tissue allografts play a key role in supporting minimally invasive surgeries by providing ready-to-use, donor-derived tissues that promote healing and simplify the surgical process. These allografts improve patient outcomes by protecting and repairing damaged tissues while minimizing recovery periods and procedural trauma. For example, in June 2024, the American Society of Plastic Surgeons reported that minimally invasive procedures grew by 7% in 2023, outpacing traditional surgeries by 2%. This increasing preference for minimally invasive approaches is thus fueling growth in the soft tissue allograft market.

Leading companies in this market are focusing on innovations in tissue processing and sterilization, such as developing resorbable soft tissue allografts to enhance repair, reduce recovery times, and improve outcomes. Resorbable soft tissue allografts are donor tissues designed to provide temporary support and gradually dissolve as the patient’s own tissue regenerates. For instance, in June 2024, Axogen Inc., a US medical technology firm, launched the Avive Soft Tissue Matrix - a resorbable, multi-layer amniotic membrane allograft that acts as a soft tissue barrier. This product offers temporary protection and separation of tissues during critical peripheral nerve healing phases, helping to safeguard nerves from damage and reduce scar formation. It is specifically designed for patients with compression or non-transected nerve injuries, aiming to prevent nerve tethering and support tissue repair. The multi-layer structure also allows for easy handling and suturing during surgery, representing a notable advancement in nerve protection for various peripheral nerve conditions.

In April 2022, ISTO Biologics, a US-based orthobiologics company, acquired TheraCell Inc., a regenerative medicine company specializing in soft tissue allografts for orthopedic and spinal repair. This acquisition aims to broaden ISTO Biologics’ portfolio by integrating TheraCell’s regenerative and bone-healing technologies to enhance surgical solutions and improve patient outcomes across spine, orthopedic, and sports medicine fields.

Major players in the soft tissue allograft market are Stryker Corporation, B. Braun Melsungen AG, Zimmer Biomet, Smiths Group plc, Arthrex Inc., Institut Straumann AG, Integra LifeSciences Holdings Corporation, CONMED Corporation, MTF Biologics, MiMedx Group Inc., RTI Surgical Holdings Inc., LifeNet Health, AxoGen Inc., Allosource Inc., Xtant Medical Holdings Inc., Acera Surgical Inc., Skye Biologics Inc., StimLabs LLC, Applied Biologics LLC, Bone Bank Allografts, Human Regenerative Technologies LLC, and Sabra Dental Products Inc.

North America was the largest region in the soft tissue allograft market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in soft tissue allograft report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the soft tissue allograft market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

A soft tissue allograft is a type of transplant in which tissue from a human donor is used to repair, replace, or reinforce damaged soft tissues in a patient. It provides structural support and promotes healing. These allografts are commonly employed in surgical procedures to facilitate recovery when the patient’s own tissue is unavailable or insufficient for effective repair.

The primary types of soft tissue allograft include cartilage allografts, tendon allografts, meniscus allografts, dental allografts, and others. A cartilage allograft is a transplant of donor cartilage tissue, typically harvested from joints such as the knee, ankle, or shoulder, preserved and processed to replace damaged or degenerated cartilage in another individual. Processing methods include fresh frozen, irradiated, dehydrated, sterilized, and others. Distribution occurs through direct sales, distributors, e-commerce platforms, and healthcare professionals. Applications include musculoskeletal repair and reconstruction, vascular surgery, cardiothoracic surgery, plastic and reconstructive surgery, dental surgery, and more. End users include hospitals, ambulatory surgical centers, rehabilitation centers, academic research institutions, and private clinics.

The soft tissue allograft market research report is one of a series of new reports that provides soft tissue allograft market statistics, including soft tissue allograft industry global market size, regional shares, competitors with a soft tissue allograft market share, detailed soft tissue allograft market segments, market trends and opportunities, and any further data you may need to thrive in the soft tissue allograft industry. This soft tissue allograft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The soft tissue allograft market consists of sales of amniotic membranes, nerve allografts, fascia lata grafts, bone-tendon-bone (BTB) allografts, and pericardial patches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.